Proteomics Products & Reviews

Twist Biopharma, a division of Twist Bioscience, provides services to help accelerate the way our partners discover and optimize antibody therapeutics with our unique DNA writing technology. Twist constructs proprietary antibody libraries precisely designed to match sequences that occur in the human body giving our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

The ExoBrite™ True EV Membrane Stains are designed to surpass the limitations of traditional membrane dyes and provide near-complete coverage of EVs with unmatched solubility, ensuring accurate and reliable results in your experiments.

Target Sufficiency® is the ability of a target system to respond to a therapeutic. It reflects the abundance and forms of the drug target protein, as well as other key system proteins that connect the target to disease phenotypes and enable response. Assessment of the target system requires an analysis platform that can simultaneously capture multiple precise protein measurements.

Syngeneic urothelial carcinoma model for bladder cancer research and immunotherapy development

Highly metastatic murine alveolar lung carcinoma cell line, derived from the CMT 64 line, that is widely used to investigate metastasis, immune responses, and immunoresistance.

The Protein A and Protein G Quantification Kits extend the Amperia™ Protein Quantification System for streamlined measurement of antibodies across subclasses and species. Using Fc capture with an inverse-occupancy format, the kits deliver reproducible titres directly from crude or clarified samples, with up to 320 tests per kit.

The Biotage® Initiator+ Alstra™ simplifies solid phase peptide synthesis with an intuitive interface for easy, customizable workflows. Step-by-step programming, robotic reagent handling, and patented oscillating mixing ensure precise delivery, consistent performance, and uniform resin distribution—delivering accurate, reproducible results for peptides and peptide-like compounds.

Rapidly synthesize high-quality peptides with microwave-assisted chemistry—enhancing yield, reducing cycle times, and lowering reagent costs using a compact, versatile workstation.

The AAV-TAb custom ELISA allows for the determination and quantification of total antibody binding to AAV vectors of different serotypes, including any potential custom capsid. This is achieved using your unique AAV preparation, eliminating the need for a surrogate AAV. Embrace the simplicity and flexibility of our two-step ELISA TAb.

Magne™ Protein G and Magne™ Protein A Beads are magnetic affinity beads with high specificity and high capacity for purification of immunoglobulins from cell culture media, ascites and serum samples.   These paramagnetic beads are composed of iron encapsulated in macroporous cellulose with low nonspecific binding. The magnetic beads use a novel attachment chemistry to immobilize recombinant Protein G or Protein A protein…

The AttoPhos® AP Fluorescent Substrate System provides a highly sensitive fluorescent alkaline phosphatase substrate.   The system includes AttoPhos® Substrate, AttoPhos® Buffer and Calibration Solution. AttoPhos® Substrate (2′-[2-benzothiazoyl]-6′-hydroxybenzothiazole phosphate [BBTP]) is cleaved by alkaline phosphatase to produce inorganic phosphate (Pi) and the alcohol, 2′-[2-benzothiazoyl]-6´-hydroxybenzothiazole (BB…

The TnT® Quick Systems are convenient single-tube, coupled transcription/translation reactions for eukaryotic cell-free protein expression.   These cell-free expression systems combine the RNA Polymerase, nucleotides, salts, amino acids and Recombinant RNasin® Ribonuclease Inhibitor with the reticulocyte lysate solution to form a single TnT® Quick Master Mix. The TnT® Quick Coupled Transcription/Translation System is ava…

The TNT® Coupled Reticulocyte Lysate Systems offer researchers an alternative for eukaryotic cell-free protein expression: a single-tube, coupled transcription/translation system. The TNT® Lysate Systems greatly simplify the process and reduce the time required to obtain in vitro translation results.

Recombinant or purified CA19-9 antigen, a sialylated Lewis blood group antigen, which is a widely used serum biomarker for pancreatic and gastrointestinal cancers.

High-purity proteins produced through genetic engineering in heterologous expression systems, ensuring consistency, scalability, and reduced lot-to-lot variability for research and development.

Recombinant Human Programmed Death-Ligand 1 (PD-L1/CD274/B7-H1), the primary ligand for PD-1, expressed on tumor and immune cells to suppress anti-tumor immunity.

Recombinant Human Bone Morphogenetic Protein 7 (BMP-7), a TGF-β superfamily member that induces bone and cartilage formation and plays roles in renal development and repair.

An extensive collection of recombinant Cluster of Differentiation (CD) proteins, which are key cell surface markers for immunophenotyping, immune function studies, and therapeutic targeting.

Recombinant Human Bone Morphogenetic Protein 2 (BMP-2), a key regulatory protein that induces bone and cartilage formation, used extensively in orthopedics and stem cell differentiation.

Recombinant Human Apolipoprotein E (ApoE), a key protein in lipid metabolism that plays a central role in cardiovascular health and Alzheimer's disease pathogenesis.

Recombinant Human B-cell lymphoma 2 (BCL-2) protein, a key regulator of apoptosis (programmed cell death) and a well-established oncoprotein in many cancers.

Recombinant Human B-cell Antigen Receptor Complex-associated protein alpha chain (CD79A), a essential component of the B-cell receptor (BCR) and a marker for B-cell lineage.

A focused set of recombinant immune regulatory proteins, such as PD-1, PD-L1, and CTLA-4, essential for research and drug discovery in cancer immunotherapy and autoimmunity.

Recombinant proteins specifically relevant as E3 ligases or target proteins for Proteolysis Targeting Chimeras (PROTACs), enabling the development of this novel targeted protein degradation technology.

A portfolio of recombinant immunoglobulins and cell surface proteins serving as critical targets for the development and functional validation of Chimeric Antigen Receptor T-cell (CAR-T) therapies.